Literature DB >> 17162706

Clinical applications of mifepristone.

Oi Shan Tang1, Pak Chung Ho.   

Abstract

Mifepristone is a progesterone antagonist that has been studied for a number of clinical applications. It is a well-known abortifacient that is effective for both first- and second-trimester medical abortion when used with a prostaglandin analog. It is also an effective cervical priming agent that can be used to soften the cervix before surgical evacuation. Its clinical efficacy as an emergency contraception has been proven. Other applications including treatment for fibroids, endometriosis and various cancers have been explored. However, its association with abortion limits the applications of mifepristone in many of these areas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17162706     DOI: 10.1080/09513590601005946

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  6 in total

1.  Megestrol Acetate Increases the Proliferation, Migration, and Adipogenic Differentiation of Adipose-Derived Stem Cells via Glucocorticoid Receptor.

Authors:  Jong-Hyuk Sung; Hyo-Sun An; Jin-Hyun Jeong; Soyoung Shin; Seung Yong Song
Journal:  Stem Cells Transl Med       Date:  2015-05-13       Impact factor: 6.940

2.  Mifepristone (RU486), a pure antiprogesterone drug, in combination with vinblastine for the treatment of progesterone receptor-positive desmoid tumor.

Authors:  A Halevy; I Samuk; Z Halpern; L Copel; J Sandbank; Y Ziv
Journal:  Tech Coloproctol       Date:  2010-06-29       Impact factor: 3.781

3.  Emergency contraception: an updated review.

Authors:  M Guida; M L Marra; V Palatucci; R Pascale; F Visconti; F Zullo
Journal:  Transl Med UniSa       Date:  2011-10-17

4.  The use of mifepristone in abortion associated with an increased risk of uterine leiomyomas.

Authors:  Qi Shen; Li Shu; Hui Luo; Xiaoli Hu; Xueqiong Zhu
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

5.  Quantitative analysis of RU38486 (mifepristone) by HPLC triple quadrupole mass spectrometry.

Authors:  Natalie Z M Homer; Rebecca M Reynolds; Cecilia Mattsson; Matthew A Bailey; Brian R Walker; Ruth Andrew
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-12-27       Impact factor: 3.205

Review 6.  Cervical ripening before first trimester surgical evacuation for non-viable pregnancy.

Authors:  Kylie Webber; Rosalie M Grivell
Journal:  Cochrane Database Syst Rev       Date:  2015-11-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.